Clinical Trial

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2021-12-17; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2022-08-25
Trial Details
NCT Number NCT05180097
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Merck Sharp & Dohme LLC, Pfizer, Australasian Leukaemia and Lymphoma Group
Conditions Hodgkin Lymphoma
Enrollment 84 participants
Start Date 2022-11-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-02